Tag:
adjuvant
Latest Headlines
Latest Headlines
Feds ok Iomai Phase II adjuvant patch study
Health and Human Services is giving Iomai the green light to do a mid-stage dose ranging study of its adjuvant patch for bird flu vaccine. HHS provided a $128 million contract backing Iomai's effort
Iomai gets boost in bird flu vaccine adjuvant study
In a Phase I/II trial, three out of every four people in a study of 500 people using an adjuvant patch developed by Iomai achieved a protective immune response after a single dose. That compares to
ALSO NOTED: Visiomed, Clinical Cell Culture to merge; Genzyme wants to reopen merger vote; Vical touts adjuvant data; and much
> Visiomed Group and Clinical Cell Culture are merging into a $27 million biotech company.
Press Release: Novartis Gains Access to Intercell's Key Technologies and Vaccines Programs
Press Release: Novartis Gains Access to Intercell's Key Technologies and Vaccines Programs
Press Release: GlaxoSmithKline initiates head-to-head study of cervical cancer vaccines
Press Release: GlaxoSmithKline initiates head-to-head study of cervical cancer vaccines
Press Release: GSK Awarded $63 Million HHS Contract for Pandemic Vaccine Research and Development
Press Release: GSK Awarded $63 Million HHS Contract for Pandemic Vaccine Research and Development
Press Release: Juvaris BioTherapeutics Announces First Round Closing Of Series A Financing
Press Release: Juvaris BioTherapeutics Announces First Round Closing Of Series A Financing
Bird flu vaccine effective in animal trial
Vical says its bird flu vaccine proved 100 percent effective in protecting ferrets from bird flu. Vical announced earlier that two doses of DNA vaccine was effective in protecting mice and ferrets. Vical's vaccine candidate is mixed with Vaxfectin adjuvant and viral proteins. Vical says it wants to begin human trials as soon as possible.- here's the AP …
Low-dose bird flu vaccine effective in trial
China's Sinovac Biotech says that its low-dose bird flu vaccine proved effective in generating an immune response from 80 percent of the 120 volunteers taking part in the trial. The vaccine was developed by using a part of the whole H5N1 virus and combining it with an adjuvant that increases the potency of the therapy. Researchers have been scrambling to find a low-dose vaccine that might work against bird flu. A low-dose vaccine would make it possible to produce enough vaccines to …
ALSO NOTED: Takeda, Galaxy Biotech ink licensing deal; Protalex raises $15.2M in private placement; and much more...
> Antigenics has expanded its licensing and supply deals for QS-21 Stimulon adjuvant with a vaccine division of GlaxoSmithKline. Release > New Hope, PA-based Protalex has raised approximately $15.2 million in a private placement of 6.1 million shares of common stock. …
- « first
- ‹ previous
- 1
- 2
- 3
- 4
- next ›
- last »
